

Assessment details

ID 121562

Name Italy_Study 308771 retrospective use of data_PIA

Organization Research & Development

Description

This document is a redacted version of the DPIA carried out on the OneTrust Platform

Completed date 02/11/2026 07:26 PM

Date submitted 02/04/2026 09:51 AM

Last updated 02/11/2026 07:26 PM

Stage Completed

Result Approved

Result comments

This DPIA serves to demonstrate compliance to the Italian legal requirement and Garante's provision for the re-use of patient' personal information.

For Italy, lawful basis for processing in the consent for the patients that are reachable. If patients are not reachable or deceased, we shall complete the tasks mandated by the Italian Privacy Code 101/2018 art. 110 and 110bis and the Garante's provision 10016146, dated 09May24.

Primary record name Italy_Study 308771 retrospective use of data

Assessment questions

1 General Information

1.1 What is the name of the business activity processing personal information?

Please type the name of the activity in an understandable and recognisable way

Response

Italy_Study 308771 retrospective use of data | Research & Development

Justification

None

1.2 Please describe the business activity processing personal information, including the purpose.

Please describe the business activity in detail and how you intend to use the personal information of individuals to achieve your aims. Specifically:

- What do you want to achieve?
- How are you going to achieve this?
- How will personal information be used to do this?
- What is the benefit to GSK and to the individual?

Personal information is information that can be used to identify you directly or indirectly, on its own or when combined with other information.

Some examples of personal information are: Name / phone number / address / date of birth / bank account details / unique identifiers / social media posts / geotagging / staff number / IP address / video image

Response

Response

The business activity is to conduct a multi-site retrospective, non-interventional study. The individuals involved for this PIA will be non-reachable patients. The study is a multi-site retrospective, non-interventional chart review study that uses longitudinal, RWD from routine medical records to analyze adult patients with MMRp/MSS primary advanced or recurrent endometrial cancer (EC) who received dostarlimab 1L as part of Compassionate Use Programs (CUP) in Italy.

"Retrospective" means using data that was already collected in the past.

The CUP includes Name Patient Program (NPP) and Expanded Access Program (EAP). A NPP was opened once the results from the RUBY Part.1 study were published. The possibility of requesting dostarlimab in association with carboplatin and paclitaxel through NPP remained available for both MMRp/MSS and dMMR/MSI-H patients until January 31st, 2024. On April 17th, 2025, an EAP was opened for the treatment of adult patients with MMRp/MSS primary advanced or recurrent EC and who are candidates for systemic therapy with dostarlimab in combination with carboplatin-paclitaxel and is currently ongoing. According to the Italian Medicines Agency (AIFA) guidelines on observational studies published in August 2024, data coming from Compassionate Use programs can only be gathered retrospectively.

To comply with this guideline, the study has been set up in two phases:

1. Phase 1: retrospective collection on patients treated with dostarlimab in combination with carboplatin-paclitaxel coming from one NPP hospital - IRCCS Gemelli hospital (i.e., start of dostarlimab plus chemotherapy (carboplatin + paclitaxel) during 01 March 2023 – 31 January 2024). Even if NPP includes patients with MMRp/MSS and dMMR/MSI-H, only MMRp/MSS patients will be included in this retrospective study.

2. Phase 2: retrospective collection on patients treated with dostarlimab in combination with carboplatin-paclitaxel during EAP plus NPP sites including Gemelli from phase I (i.e., start of dostarlimab plus chemotherapy (carboplatin + paclitaxel) during 01 March 2023 – 31 January 2024, and 17 April 2025-Q2 2026)

The objectives of this study are to describe the treatment of dostarlimab in combination with carboplatin/paclitaxel for the first-line treatment of adult patients with MMRp/MSS primary advanced or recurrent endometrial cancer in the Compassionate Use Programs: NPP for phase 1 of the study and NPP+EAP for phase 2 of the study.

The study does not impose a treatment protocol, any diagnostic/interventional procedure, or a visit schedule.

Individual-level data on patients with MMRp/ MSS primary advanced or recurrent EC treated with dostarlimab 1L will be analyzed.

Eligible patients from Italian CUP will be included in the study.

The study will collect data of approximately 30 patients within the NPP, and approximately 100 patients from EAP.

Written informed consent (if required based on local regulatory and legal country requirements) will be obtained from all reachable patients before enrolment into the study.

The name of the GSK legal entity who is sponsor for the study is GlaxoSmithKline SpA.

The process flow from chart review to data entry in the Electronic Data Capture (EDC) system involves the following steps and parties:

Chart Review and Data Extraction:

Site Investigators or designated site personnel review patient medical records to extract relevant data, including baseline characteristics, study outcomes, and other pertinent information. The medical record serves as the source document for this information.

Data Entry into Electronic Data Capture (EDC): Clinical.net is the database used De-identified data (pseudo-anonymous to non-site staff) is transferred from the patient's medical record into the electronic Case Report Form (eCRF) within the EDC system. The EDC system is designed to minimize errors with built-in logic checks to prevent missing or illogical data.

Verification and Quality Assurance:

Site Investigators are responsible for ensuring the accuracy and timeliness of data entry.

Study monitors from the vendor OPIS perform remote visits to confirm that data entered into the eCRF is accurate, complete, and verifiable from source documents.

OPIS will act as data processor appointed under art. 28 GDPR.

Data Management and Storage:

All data extracted is stored on secure servers, ensuring compliance with local or national regulations.

Findings will be disseminated through scientific publications and presentations in an aggregated, anonymous manner.

Timelines

Start of data collection: Q1 2026

End of data collection: Q3 2028

Final report of study results: Q4 2028

The level of access to personal information (PI) for different study roles is as follows:

Study Staff:

Full access to personally identifiable information (PI) such as name, address, phone number, and health insurance number.

Responsible for collecting and storing PI securely at the study site.

CRO (OPIS - data processor appointed by GSK):

Access to coded data only.

Does not have access to direct identifiers like name or contact details.

GSK Team:

Access to coded data only.

Coded data is anonymized once the code list is destroyed, ensuring no linkage to the participant.

IRBs/IECs and Regulatory Authorities:

May review study records, including PI, to ensure compliance with legal and quality requirements.

Appropriate measures are taken to protect PI, and direct identifiers are never sent to GSK or CROs.

This questionnaire and the subsequent PIA are necessary to assess the feasibility to collect data for the Italian patients that are either deceased or not reachable and so their consent cannot be obtained, in compliance in particular to the Italian Privacy Code 101/2018 articles 110 and 110 bis

Justification

None

1.3 When is the expected start date of the activity?

Select the date that the activity is due to start or started if the date is in the past.

Response

Italy_Study 308771 retrospective use of data | Research & Development

Response

12/10/2025

Justification

None

1.4 When is the expected end date of the activity?

Select an end date if this is a one-off activity, project or initiative.
Select "Not Applicable" if this is an ongoing activity with no end date.

Response

Italy_Study 308771 retrospective use of data | Research & Development

Response

12/31/2028

Justification

None

1.5 Is this a global or a local activity?

A local activity involves one market.

A global activity will involve multiple (two or more) markets or personal Information of individuals located in multiple markets.

Response

Italy_Study 308771 retrospective use of data | Research & Development

Response

Local

Justification

None

1.6 Which country is the privacy contact reviewing this business activity responsible for?

Please only select one country.

Response

Italy_Study 308771 retrospective use of data | Research & Development

Response

Italy

Justification

None

1.7 Who decides why and how personal information is processed as part of this activity? Please select the appropriate GSK entity for this activity.

This is known as the controller in some jurisdictions.

If one entity is involved in determining the purpose and design of this business activity, please begin by typing the country it is associated with to filter the drop-down results.

If multiple entities are involved in determining the purpose and design of this business activity, please either select the specific entities or regions involved.

The regions available for selection are:

- Africa
- Asia-Pacific
- Australia
- Canada
- Central America/Caribbean/Mexico
- Europe
- Middle East
- South America
- United States

Please refer to guidance examples [for controller and processor here](#).

Response

ITALY GlaxoSmithKline S.p.A | Privacy | Italy

Justification

None

1.8 Who processes personal information as part of this activity but is not involved in deciding why and how personal information is processed? Please select the appropriate GSK entity(ies) for this activity.

This is known as the controller in some jurisdictions.

If one entity is involved in determining the purpose and design of this business activity, please begin by typing the country it is associated with to filter the dropdown results.

If multiple entities are involved in determining the purpose and design of this business activity, please either select the specific entities or regions involved.

The regions available for selection are:

- Africa
- Asia-Pacific
- Australia
- Canada
- Central America/Caribbean/Mexico
- Europe
- Middle East
- South America
- United States
- Not Applicable

Please refer to guidance examples [for controller and processor here](#).

Response

Not applicable

Justification

None

1.9 Does the activity consist of any of the following high risk features or is there any other reason a Privacy Impact Assessment (PIA) is required?

Some of these activities will trigger a PIA to be completed, others will only require a PIA when multiple activities are combined.

A Privacy Contact or Leader may ask you to complete a PIA in some circumstances where it is not automatically triggered.

Please hover over each option below to obtain a further explanation.

Response

Italy_Study 308771 retrospective use of data | Research & Development

Response

Processing of sensitive personal information Processing of information concerning vulnerable individuals PIA is required by the Data Privacy Authority

Justification

None

2 Personal Data

2.1 Please select the group(s) of individuals whose personal information will be processed. For each group, select the categories of information and individual data elements processed.

Remember that any information that GSK could identify an individual through, directly or indirectly, on its own or in combination with other personal information we hold, should be selected.

Please include all the personal data elements that you reasonably expect could be collected for this activity.

Response

Research Subjects

Restricted Elements

Personal contact details

Age or date of birth

Key Coded Data

Sensitive Elements

Medical or Health Information

Ethnicity or Race

Basic Elements

Gender or Title

First / Lastname

2.2 How many individuals' personal information will be used to carry out this business activity?

Please estimate the number of individuals whose data is processed for this activity. If the activity does not have an end date, please provide an annual estimate.

Response

Italy_Study 308771 retrospective use of data | Research & Development

Response

0-1000

Justification

None

2.3 Where will the individuals be located whose personal information will be used for this business activity?

Please select all locations individuals are located, you can select multiple options.

In certain jurisdictions, individuals will be referred to as data subjects.

Response

Italy_Study 308771 retrospective use of data | Research & Development

Response

Europe

Justification

None

2.4 Please select the appropriate basis for processing the personal information.

You must have a valid basis to carry out your business activity. No single basis is 'better' or more important than the others – which basis is most appropriate to use will depend on your purpose and relationship with the individuals.

If consent is only used as an appropriate condition for processing sensitive personal information, and not as a lawful basis, please only select consent in the following question.

If selected, please explain the legal obligation in the justification box including name of statute or regulation and section references where possible.

If selected, please explain the contractual obligation in the justification box including name or reference for the related contract(s), where possible.

Response

Italy_Study 308771 retrospective use of data | Research & Development

Response

Consent of the individual Italian Privacy Code 101/2018 art. 110 and 110 bis. Garante's provision 10016146, dated 09May24

Justification

None

2.5 Please select the appropriate condition for processing the sensitive personal information.

Sensitive personal information needs more protection because, due to its sensitivity, it poses a higher risk to individuals if it is misused.

You must determine an additional condition for processing sensitive information before you begin this processing.

Please hover over each option below to obtain a further explanation.

Response

Italy_Study 308771 retrospective use of data | Research & Development

Response

Italian Privacy Code 101/2018 art. 110 and 110 bis. Garante's provision 10016146, dated 09May24 Explicit consent

Justification

None

3.1 Describe the rationale for using the volume and categories of personal information selected

Please explain why the number of information types and numbers of individuals involved are relevant and necessary to achieve the aims of this activity.

Response

The volume and categories of personal information used in this study are selected to achieve the study's objectives effectively as described in the study protocol. The study will be collecting relevant data from medical records for patients with endometrial cancer as detailed in the study protocol. Volume of data: based on patients who received treatment through compassionate use program in Italy and deemed sufficient to have insights on real world progression-free survival of MMRp/MSS patients with a primary advanced or recurrent endometrial cancer diagnosis that received dostarlimab plus chemotherapy in first-line.

3.2 Could your objectives be achieved with less information from fewer individuals?

Remember you should only use the information that you need. Please consider whether the same results could be achieved with less information.

Please explain your rationale in the justification box below.

Response

No

Justification

GSK ensures that only essential data is collected and processed. The data collected is limited to what is necessary to achieve the study objectives, in line with data minimization principles.

The objectives of this study could not be effectively achieved with less information or fewer research subjects. Reducing the volume of data or the number of participants could compromise the validity and reliability of the study outcomes. By its nature, real-world data can be less complete and reliable, which is why often a larger population is needed to secure validity of the results.

3.3 Is there any other way to achieve the purpose?

Consider the balance between business benefit and the privacy of individual. Could you achieve a similar benefit to the business in a way that gives greater privacy to the individual?

Please provide your rationale in the justification box below.

Response

No

Justification

There are no alternative approaches that would achieve the same purpose without processing the personal data as currently done. The insights gained from the real world data are crucial and cannot be achieved without processing personal data. The observational nature of the study relies on the collection and analysis of data to provide meaningful results.

3.4 Is all the personal information collected necessary for the intended purpose?

You should avoid collecting or using information because it is an easier option or because you might need it in future.

Do you need to use each personal information type you are collecting for this business activity?

Please explain your rationale in the justification box below

Response

Yes

Justification

Yes, GSK will ensure that each data element collected is essential for achieving the study objectives and ensuring the validity and reliability of the findings.

3.5 Will the data collected be used for anything other than the specified purpose?

Personal information should only be used for the purposes (e.g. business activities) for which it was collected. It should only be used for other purposes if they are compatible with the original purpose for which it was collected.

Consider whether any other GSK colleagues or teams have access to the data and be able to use it for their own purposes. Are these purposes compatible with or similar to the purposes for which it was collected?

Please explain your rationale in the justification box below if you select 'Yes'.

Response

No, the personal information will only be used for the purpose stated in question 1.2.

Justification

Personal data will be used according to the information provided in question 1.2

4 Consent

4.1 How do individuals provide consent for their information to be collected?

Opt-in consent requires user action to confirm they do want their data included and processed in this way, with data not processed unless confirmation provided. Examples of opt-in are:

- Signature box
- Tick box asks user to select to confirm they want their personal data used for this activity
- Verbal agreement (documented by GSK)

Opt-out consent tells individuals that their consent is deemed to have been given, unless there is user action to notify GSK that they do not want their data included in the activity, with data not processed only if notification provided. Examples of opt-out are:

• Tick box asks for user to select if they do not want their personal information used for this activity.

Continuing without objection is where an individual is deemed to have given consent unless they tell us otherwise. Examples include:

- Continuing to use a website after seeing a cookie pop up. (this would not be acceptable under the GDPR)
- "By using this site / continuing with this form you consent to..."

Response

Italy_Study 308771 retrospective use of data | Research & Development

Response

Opt-in

Justification

None

4.2 Can individuals change their consent preferences, for example withdraw their consent, at any time?

Most privacy laws require that if an individual provides consent, they should be able to withdraw their consent in a way that is as easy as those for giving consent.

If individuals cannot change their consent preferences, please provide a rationale for why this is acceptable or an alternate approach to managing consent in the justification box below.

Response

Italy_Study 308771 retrospective use of data | Research & Development

Response

Yes

Justification

None

4.3 How can the individual change their consent preferences?

Response

Italy_Study 308771 retrospective use of data | Research & Development

Response

Preference centre

Justification

None

4.4 What source do we obtain the personal information of individuals used in this processing activity from?

Select one or more that apply.

Please hover over the options to see more information.

Please add any further relevant information to the justification box below.

Response

Italy_Study 308771 retrospective use of data | Research & Development

Response

Contracted third parties

Justification

The centers, as independent data controllers, collected patients clinical data during NPP and during the EAP. As part of the Study, the Centers will be responsible for removing all patient identifiable information and will ensure that the data is pseudonymized in eCRF.

4.6 Please select the third party the personal information is collected from, from the drop down list.

If the third party is not available in the drop-down list, please select not sure and let your privacy lead or privacy contact know.

Response

9910018128 - OPIS SRL | TPRM | Unknown

Justification

None

5 Individual Rights

5.1 Can a copy of the personal information used for this activity be provided to an individual upon request?

An individual may have the right to request a copy of their personal information in certain countries. For example, under the GDPR this is called a Data Subject Access Request and we have one month to respond. Email, excel, word, pdf, etc is an acceptable format.

Please use the justification box below to provide a rationale if 'No' is selected.

Response

Yes - information can be provided in a digital format (e.g. files, images, recordings, etc.)

Justification

In case of data collection by GSK, GSK has an Individual Rights Request (IRR) process in place. Moreover, for study records, patients are invited (as specified in the ICF and privacy consent form) to contact their study staff. Data can potentially be provided in digital format.

5.2 Is there a mechanism or process to ensure the personal information is kept accurate and can be updated when required?

We must keep personal information accurate while we hold it. Please describe how we identify inaccurate personal information and correct it when it is inaccurate or out of date.

Response

Yes

Justification

Data collection process involves a level of data validation. Built in mechanisms exist to correct typing errors, field verification, data formats, range checking. Study specific checks, which are specifically programmed to verify whether the inputted data is correct, are put in place.

5.4 Is there a process in place for when an individual asks for GSK to stop using their information?

In some circumstances individuals may be able to ask us to restrict the use of their personal information. This means that GSK would be allowed to store the information but not use it.

Requests to restrict processing are most common when information is held longer than it should be or where there is a legal challenge.

If we had to stop using the personal information of one individual, could we continue the activity that their information was used for without impact?

Response

Yes

Justification

The study gathers data from electronic medical records provided to a third party in pseudonymized form. GSK does not hold identifiers and cannot trace or isolate individual records. Any data subject rights, including requests to restrict processing, must be managed by the original data holders (participating study sites). Reachable patients may withdraw consent contacting the study physician. Any restriction on use would need to be applied by the data holder and, if necessary, reflected in the data provided to us.

6 Access/Transfers

6.1 Where/who might the personal information be shared to/with?

Response

Italy_Study 308771 retrospective use of data | Research & Development

Response

Regulatory Authorities and Ethics committees

Justification

None

6.7 Is personal information transferred from one country to another?

Personal information is transferred when it is transmitted from one country to another across jurisdictional borders.

Please note, a transfer does not mean the same as transit. If personal data is just electronically routed through Country B, but the transfer is actually from one organisation in Country A to another in Country A and there is no intention that this information will be access or used whilst transiting through Country B, then it is not considered a transfer to another country.

Response

Italy_Study 308771 retrospective use of data | Research & Development

Response

No

Justification

None

7 Security

7.1 What is the outcome of the Third Party Security Assessment?

A Third Party Security Assessment (i.e., TPSA) is performed by the cybersecurity team on a third party and/or on its applications, systems and platforms, when GSK's cybersecurity criteria are met.

Response

Italy_Study 308771 retrospective use of data | Research & Development

Response

Reasonably Adequate

Justification

None

7.2 Has a Risk and Compliance Assessment (R&CA) (previously known as a Smart Control Assessment) been completed and submitted?

Risk and Compliance Assessment (R&CA) (previously known as a Smart Control Assessment) are defined to ensure that technology systems meet GSK and Regulatory requirements (e.g., audit trails, access management, electronic records and signatures, validation, privacy) and allow GSK to manage its main technology risks.

They must be conducted for all systems and maintained through the life of the system.

Response

Italy_Study 308771 retrospective use of data | Research & Development

Response

Yes

Justification

None

8 Transparency

8.1 Have you or will you provide individuals with a privacy notice?

Where a third party is used to provide the privacy notice, please describe how GSK evidence that the privacy information has been given to the individual. For example, if an agency / health care partner / intermediary provide privacy notice to individuals on behalf of GSK.

If multiple options apply, please provide further information in the justification box below.

Response

Italy_Study 308771 retrospective use of data | Research & Development

Response

We rely on a third party to provide the individuals with a privacy notice

Justification

None

8.2 Has the privacy notice been reviewed to ensure the processing covered?

The privacy notice is public facing and can be found on our websites.

If the activity being assessed is not covered by the existing wording, then the privacy notice may need to be updated before the activity can start.

If a third party is being used to provide a privacy notice, this should be reviewed to confirm that it includes the required information.

If you require further assistance, please speak to a Privacy Contact or Privacy Leader.

Response

Italy_Study 308771 retrospective use of data | Research & Development

Response

Yes

Justification

None

9 Retention

9.1 How long is the information held for?

Select the applicable GSK Global Retention Schedule(s) for each type of data subjects (you selected data subject types in question 2.1). If none of the GRS applies to your processing activity, please identify and mention the relevant retention period(s) in the justification box below.

As an example: Employees: employee records (GRS056 - 7 years after employment ends) HCP: Healthcare Events Programme Records (GRS101 - <10 years).

If you are unsure, please access the [GSK Global Records Retention Schedule](#).

Response

Italy_Study 308771 retrospective use of data | Research & Development

Response

10 years

Justification

None

9.2 When does the retention period start from (trigger)?

This is the point from which the clock starts for deletion, this is often at the end of a relationship, closure of an account, the date a clinical trial ends.

For example, the period of retention for GSK employee personal information, only starts when an individual leaves employment. The trigger period, therefore, is when an employee ceases their employment with GSK.

Personal information will be kept for the length of the retention period from the trigger date, it will then be disposed of at the end of the retention period.

Response

From CSR signature

9.4 Is digital personal information automatically deleted and is hard copy personal information scheduled for deletion on a periodic basis?

Where information is used digitally, is there a process that destroys information (or puts in beyond use) without human input?

Where information is stored physically, for example in archive, is there a process to ensure that the information is destroyed regularly?

If the answer to either is No, please select No as the answer and provide an explanation.

Response

Yes

Justification

GSK does not receive personal information, only pseudonymized data report.
Third party vendor archives pseudonymized data for 10 years.

9.5 Can you prevent automatic and/or scheduled deletion from taking place?

If we needed to, could automated deletion be paused or stopped? For example if we needed to keep information as part of a legal dispute, could it be kept longer than the original intended retention period?

Response

Yes

Justification

Yes we would be able to prevent deletion of data, if needed.

9.6 How does GSK ensure personal information is managed in line with the retention period?

This is particularly important where retention and deletion processes are not automated or where information is not stored in a structured system.

Please describe the processes or controls that will help us understand how long information is being held for and will ensure that it is deleted at the right time

Response

Third party vendor archives pseudonymized data for 10 years from the conclusion of the study. GSK is notified when data is deleted.

9.7 Can GSK delete the personal information on request?

In some countries individuals can ask for their information to be deleted, if we were asked to delete information by an individual, could their information be deleted? If information may not be deleted or there may be difficulties deleting it, please provide details.

If no is selected please provide a rationale in the justification box below.

Response

Yes

Justification

The data used for this activity is pseudonymized and cannot be attributed to identifiable individual without additional information held separately by the participating study site personnel. Consequently, we cannot determine whether a specific individual is included in the dataset. Should GSK receive a deletion request from an individual, it will be forwarded to the appropriate data holder for action.

9.8 Please provide the GSK Global Retention Schedule (GRS) number(s).

Please enter the relevant GRS numbers for the data elements collected for this processing activity. For more information on GRS numbers, you can consult the [GSK Global Records Retention Schedule](#).

Response

Italy_Study 308771 retrospective use of data | Research & Development

Response

retention of 10 years for both data stored by GSK and by the TP vendor from the conclusion of the study.

GRS040 for GSK (Supportive Regulatory Information - Key records relating to obtaining and maintaining product registrations but not submitted to an agency or 3rd party).

GRS050 for TP (CRO) (Contracts / Agreements - Documentation detailing the legally binding terms and conditions of agreements between the Company and other people / organisations).

Justification

None

10 Consultations

10.1 Who has been consulted as part of the activity?

It may be beneficial to seek opinion of others to fully consider risks and benefits. For example HR and/or Trade Union Representatives may be consulted for high risk change impacting GSK employees You can add links or upload output.

Response

Country Privacy Advisor for Italy

11 Supporting Information

11.1 (Optional) Please provide links to any documentation that may support the assessment

This is optional.

Examples of supporting documentation include data flow diagrams, system architecture diagrams, stakeholder consultation output, risk discussions/acceptance etc.

Response

Not answered

12 For Privacy Contact / Privacy Lead

12.1 Is it necessary to consult with the Data Protection Authority?

If a high risk has been identified and the risk cannot be mitigated, it may be necessary to consult with the Data Protection Authority

Response

Yes

Justification

Yes, this is a requirement for Italy

12.2 (Optional) Additional Comments

Response

Not answered

13 Risks

13.2 Based on the answers provided, there is a risk that individuals are not informed about how GSK use their information and their rights in relation to the information, or that the activity is unexpected.

Questions answered that triggered risk:

Have you or will you provide individuals with a privacy notice? Answer: We are not required to provide individuals with a privacy notice for this activity.

or

Have you or will you provide individuals with a privacy notice? Answer: We rely on a third party to provide the individuals with a privacy notice.

or

Has the privacy notice been reviewed to ensure the processing is covered? Answer: No

Have you or will you put in place any actions to mitigate the risk? Select Yes and use the justification box below to detail any mitigating actions taken. If No, use the justification box below to detail how this risk was accepted or closed.

Response

Italy_Study 308771 retrospective use of data | Research & Development

Response

No

Justification

The privacy notice will be published on GSK public website, available for all individuals

13.15 Are there any other risks that you have identified?

If so, please detail them in the box below.

Response

No other risks have been identified.

Informativa sul trattamento dei dati personali

Studio 308771

Premessa

I Suoi dati, in particolare quelli personali e quelli sulla salute e soltanto nella misura in cui sono indispensabili in relazione allo scopo dello studio, verranno trattati nel rispetto del Regolamento Generale sulla Protezione dei Dati Personali EU 679/2016 (GDPR) e il Decreto legislativo n. 196/2003 così come modificato dal D.lgs. 101/2018 e ss.mm. I documenti relativi ai partecipanti saranno custoditi in luogo sicuro e non riporteranno i nominativi in chiaro, noto solo ai ricercatori, ma solo un codice identificativo.

Il Regolamento Generale sulla Protezione dei Dati Personali (GDPR) dell'Unione Europea stabilisce che GSK e i Centri, in qualità di titolari autonomi del trattamento dei dati, devono indicare le basi legali del trattamento delle informazioni personali (Articolo 6.1). Le basi giuridiche seguite da GSK sono di seguito riportate:

Tipo di informazioni personali	Base giuridica del GDPR
Informazioni sullo Studio (dati identificativi, dati sanitari) Origine etnica	Coerente con il legittimo interesse del titolare del trattamento ai sensi dell'Articolo 6.1 (f), e ai sensi dell'articolo 9.2 (g) e (j), perché il trattamento di categorie speciali di dati è necessario per la ricerca scientifica per motivi di interesse pubblico rilevante e sulla base del diritto dell'Unione o degli Stati membri, nonché ex art. 110 e 110bis del d.lgs. 196/2003.

Le Sue informazioni personali non saranno utilizzate per valutazioni eseguite mediante processi automatizzati senza coinvolgimento umano.

Perché verranno raccolti i dati codificati?

GSK utilizzerà i Suoi dati personali codificati per:

- Condurre e raggiungere lo scopo dello studio.
- Comprendere i risultati di questo studio.
- Progettare nuovi studi relativi al farmaco/vaccino in studio, alla malattia in studio e condizioni correlate.
- Pubblicare i risultati dello studio. Il Suo nome non apparirà in nessuna pubblicazione.

Come vengono protetti i Suoi dati personali? Cosa succede quando i dati vengono trasferiti?

Per proteggere i Suoi dati personali verranno adottate misure adeguate in accordo alle leggi applicabili in materia di protezione dei dati e di tutela della privacy.

I Suoi dati codificati (pseudonimizzati) potranno essere trasferiti in altri paesi a soggetti terzi che soddisfino requisiti di garanzia e che saranno contrattualmente vincolati alla protezione dei Suoi dati personali. In alcuni paesi le leggi sulla protezione dei dati potrebbero essere meno severe che in Italia. Qualora i dati personali siano trasferiti a un paese terzo o a un'organizzazione internazionale, saranno adottate tutte le garanzie previste dall'articolo 46 del GDPR 679/2016 relative al trasferimento.

Maggiori dettagli sulle misure di tutela sono consultabili agli indirizzi:

- https://commission.europa.eu/law/law-topic/data-protection/international-dimension-data-protection/standard-contractual-clauses-scc_en (Clausole contrattuali standard della Commissione europea per il trasferimento internazionale);
- https://ec.europa.eu/info/index_en
- <https://www.gsk.com/en-gb/about-us/policies-codes-and-standards/binding-corporate-rules/> (GSK's Binding Corporate Rules)

Quali sono i Suoi diritti relativi ai Suoi dati?

Lei gode di alcuni diritti di cui riteniamo necessario informarla. In alcune circostanze, alcuni Suoi diritti potrebbero essere limitati, ad esempio da requisiti legali per conservare una copia dei documenti di studio o per proteggere l'integrità scientifica di uno studio.

Lei ha il diritto:

- di conoscere con maggior dettaglio come vengono trattati i Suoi dati;
- una copia dei Suoi dati;
- di correggere le informazioni che Lei ritiene inesatte o incomplete;
- di richiedere la cancellazione dei Suoi dati;
- di chiedere l'invio dei Suoi dati ad un altro soggetto (ad esempio il Suo medico curante) per poterli riutilizzare.

Inoltre Lei potrà:

- opporsi al trattamento dei Suoi dati;
- sporgere reclamo all'autorità competente in caso di violazione dei Suoi diritti in materia di tutela di dati personali. In Italia l'autorità competente è il *Garante per la Protezione dei Dati Personali* (dati di contatto sul sito <http://www.garanteprivacy.it>);
- richiedere il risarcimento dei danni materiali o morali patiti in ragione di un trattamento illecito dei Suoi dati.

Per effettuare tali richieste, si consiglia di contattare prima la Sua regione di residenza. GSK non può rispondere a richieste pervenute direttamente da Lei, in quanto GSK non è in possesso dei dati identificativi dei pazienti e non è in grado di tracciare o isolare i singoli pazienti.

Per quanto tempo saranno utilizzati i Suoi dati?

I dati codificati saranno utilizzati esclusivamente per il periodo necessario allo svolgimento dello Studio, successivamente saranno cancellati trascorsi 10 anni dalla conclusione dello Studio.

Chi raccoglierà e utilizzerà i Suoi dati?

Il Titolare del Trattamento dei Dati raccoglie ed elabora i dati e stabilisce a quale scopo e come essi debbano essere elaborati. GSK e il Centro sono i Titolari autonomi del Trattamento dei Dati per questo Studio. Il Responsabile della Protezione dei Dati Personali (*Data Protection Officer*) di GSK può essere contattato all'indirizzo EU.DPO@gsk.com.

Per mantenere l'anonimato, La invitiamo in prima istanza a contattare la Sua regione di residenza. GSK non è in grado di rispondere a richieste ricevute direttamente in quanto non è in possesso dei dati identificativi dei partecipanti.

Ultimo aggiornamento 24/02/2026